Isolation of bioactive proteins from natural product extracts

我们的努力已经导致了几类生物活性蛋白的发现，以及关于其潜在活性的出版物。这项研究总共获得了34项专利，不同的许可方对我们的发现非常感兴趣。最近的一些特别令人感兴趣的论文包括我们对蛋白质griffithsin （GRFT）的快速溶解配方的报告，该配方显示出对SHIV， HSV-2和HPV的体内活性，18 GRFT在水稻中与其他两种杀菌剂的表达，17导致了新的专利申请，并发现了一类新的环状肽，称为tyrl -lock肽，也导致了新的专利。PCMBS项目2成功的另一个证据是，两个不同版本GRFT蛋白的I期临床试验现已成功完成，其中一个结果已发表。我们继续这些合作，以帮助通过临床推广基于grft的产品。最后，已经启动了另外两项用于抗SARS-CoV-2的QGRFT突变蛋白鼻腔配方的I期临床试验。

Our efforts have led to the discovery of several classes of bioactive proteins as well as publications on their potential activity. This research has also led to 34 patents overall and significant interest for our discoveries from different licensees. Recent papers of particular interest include our report of fast-dissolving formulations of the protein griffithsin (GRFT) which showed in vivo activity against SHIV, HSV-2 and HPV,18 the expression of GRFT in rice with two other microbicide candidates17 which led to a new patent filing and the discovery of a new class of cyclic peptides called Tyr-lock peptides which also led to a new patent. Additional evidence for the success of PCMBS Project 2 is the fact that two Phase I clinical trials of different versions of the protein GRFT have now been successfully completed one of which whose results have been published. We continue these collaborations to help advance GRFT-based products through the clinic. Finally, two additional Phase I clinical trials of nasal formulations of the QGRFT mutant protein for use against SARS-CoV-2 have been initiated.